The CEO hypothesized that patients needed clinical follow-up to improve their post-consultation NPS. I designed a lightweight controlled experiment to test this assumption — at zero development cost. The data revealed the real problem was entirely different. This is the case that best demonstrates what good experimentation looks like.
At Blue Medical, NPS was more than a satisfaction score — it was a proxy for retention and downstream revenue. A patient who left a consultation dissatisfied was less likely to return, less likely to follow through on lab and prescription recommendations, and more likely to choose a competitor for their next visit. Improving NPS was directly linked to the cross-sell model that drove the company's revenue.